OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!
If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.
Requested Article:
Discovery of novel, potent, selective and orally bioavailable HPK1 inhibitor for enhancing the efficacy of anti-PD-L1 antibody
Shenxin Zeng, Mingfei Wu, Yuyuan Jin, et al.
European Journal of Medicinal Chemistry (2024) Vol. 267, pp. 116206-116206
Closed Access | Times Cited: 6
Shenxin Zeng, Mingfei Wu, Yuyuan Jin, et al.
European Journal of Medicinal Chemistry (2024) Vol. 267, pp. 116206-116206
Closed Access | Times Cited: 6
Showing 6 citing articles:
Discovery of PF-07265028, A Selective Small Molecule Inhibitor of Hematopoietic Progenitor Kinase 1 (HPK1) for the Treatment of Cancer
Rebecca A. Gallego, Sujin Cho-Schultz, Matthew Del Bel, et al.
Journal of Medicinal Chemistry (2024)
Closed Access | Times Cited: 4
Rebecca A. Gallego, Sujin Cho-Schultz, Matthew Del Bel, et al.
Journal of Medicinal Chemistry (2024)
Closed Access | Times Cited: 4
Discovery of Pyridine-2-Carboxamides Derivatives as Potent and Selective HPK1 Inhibitors for the Treatment of Cancer
Jingjing Peng, Xiaoyu Ding, Celia Y. Chen, et al.
Journal of Medicinal Chemistry (2024)
Closed Access | Times Cited: 3
Jingjing Peng, Xiaoyu Ding, Celia Y. Chen, et al.
Journal of Medicinal Chemistry (2024)
Closed Access | Times Cited: 3
Design, Synthesis, and biological evaluation of 7H-Pyrrolo[2,3-d]pyrimidines as potent HPK1 kinase inhibitors
Feifei Wu, Huiyu Li, Weiqiang Li, et al.
Bioorganic & Medicinal Chemistry (2025) Vol. 119, pp. 118079-118079
Closed Access
Feifei Wu, Huiyu Li, Weiqiang Li, et al.
Bioorganic & Medicinal Chemistry (2025) Vol. 119, pp. 118079-118079
Closed Access
An updated review of small-molecule HPK1 kinase inhibitors (2016-present)
Yiping Duan, Zhichao Guo, Wenyi Zhong, et al.
Future Medicinal Chemistry (2024), pp. 1-20
Closed Access | Times Cited: 1
Yiping Duan, Zhichao Guo, Wenyi Zhong, et al.
Future Medicinal Chemistry (2024), pp. 1-20
Closed Access | Times Cited: 1
Design, Synthesis, and Pharmacological Evaluation of Triazine-based PI3K/mTOR Inhibitors for the Potential Treatment of Non-Small Cell Lung Cancer
Ming Zeng, Ying-xuan Hu, Lan Zhao, et al.
European Journal of Medicinal Chemistry (2024) Vol. 284, pp. 117200-117200
Closed Access | Times Cited: 1
Ming Zeng, Ying-xuan Hu, Lan Zhao, et al.
European Journal of Medicinal Chemistry (2024) Vol. 284, pp. 117200-117200
Closed Access | Times Cited: 1
Opportunities and challenges for targeting HPK1 in cancer immunotherapy
Jiamei Xu, Ying‐Zhou Li, Xinyi Chen, et al.
Bioorganic Chemistry (2024) Vol. 153, pp. 107866-107866
Closed Access
Jiamei Xu, Ying‐Zhou Li, Xinyi Chen, et al.
Bioorganic Chemistry (2024) Vol. 153, pp. 107866-107866
Closed Access
